Shares of RxSight, Inc. (NASDAQ: RXST) plunged 35.65% in Wednesday's trading session following the company's announcement of disappointing preliminary second-quarter results and a significant downward revision of its full-year 2025 guidance.
The ophthalmic medical device company reported expected Q2 2025 revenue of approximately $33.6 million, representing a 4% decrease compared to the same period last year and falling short of analysts' expectations of $39.8 million. The revenue decline was primarily driven by a sharp decrease in sales of Light Delivery Devices (LDDs), which fell 45% compared to Q1 2025 and 49% year-over-year.
Adding to investors' concerns, RxSight significantly cut its full-year 2025 revenue guidance. The company now expects revenue in the range of $120 million to $130 million, a substantial reduction from its previous forecast of $160 million to $175 million. This revised guidance implies a year-over-year decrease of 7% to 14%, a stark contrast to the growth investors were anticipating. In response to the lowered outlook, several analysts have downgraded their price targets for RxSight, with Piper Sandler reducing its target from $18 to $10.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.